Identification of TC2N as a novel promising suppressor of PI3K-AKT signaling in breast cancer.

Although TC2N has proven to be an oncogene in lung cancer, its biological function and molecular mechanisms in other cancer still remains unclear. Here, we investigate in breast cancer that TC2N expression is sharply overexpressed in breast cancer specimens compared with normal breast specimens, and the low TC2N expression was associated with advanced stage, lymphatic metastasis, larger tumors and shorter survival time. Upregulation of TC2N significantly restrains breast cancer cell proliferation in vitro and tumor growth in vivo. Mechanistically, TC2N blocks AKT signaling in a PI3K dependent and independent way through weakening the interaction between ALK and p55γ or inhibiting the binding of EBP1 and AKT. To sum up, these results unmask an ambivalent role of TC2N in cancer, providing a promising inhibitor for PI3K-AKT signaling.

Citation

Xiang-Lin Hao, Li-Yun Gao, Xiao-Juan Deng, Fei Han, Hong-Qiang Chen, Xiao Jiang, Wen-Bin Liu, Dan-Dan Wang, Jian-Ping Chen, Zhi-Hong Cui, Lin Ao, Jia Cao, Jin-Yi Liu. Identification of TC2N as a novel promising suppressor of PI3K-AKT signaling in breast cancer. Cell death & disease. 2019 May 29;10(6):424

Mesh Tags

Substances

PMID: 31142739

search → result